Amgen launches new platform to help fix scientific ‘reproducibility crisis’ | Times Higher Education (THE)

"A major pharmaceutical company is launching a new platform for the publication of experiments that attempt to replicate previous research in a bid to tackle the 'reproducibility crisis' in science. In 2012, Amgen alarmed the scientific world by revealing that it had been able to reproduce the results of only six out of 53 “landmark” cancer studies. This confirmed similar, worrying findings from German drug company Bayer released the previous year. Launched on 4 February, the Preclinical Reproducibility and Robustness channel is on the F1000Research publishing platform, which is open access and invites peer review after publication. Bruce Alberts, a prominent biochemist at the University of California, San Francisco and former editor-in-chief of Science, said it would be a home for replication attempts that were often shunned by journals ..."